The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007.
 
Kathryn Arbour
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Genzyme; Lilly; Merck; Novartis; Regeneron; Revolution Medicines; Sanofi
Research Funding - Bristol Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Revolution Medicines (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Revolution Medicines
 
Ben George
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Bristol-Myers Squibb; Foundation Medicine; Ipsen; Roche/Genentech; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca; Taiho Oncology
Research Funding - CARsgen Therapeutics (Inst); GlycoNex (Inst); Helix BioPharma (Inst); Helix BioPharma (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Sirnaomics (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transcenta (Inst); Trishula Therapeutics (Inst); Tvardi Therapeutics (Inst)
 
Jason Henry
Employment - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbisko (Inst); ABL Bio (Inst); accutar biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Artios (Inst); AstraZeneca/Merck (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); Bioinvent (Inst); Biosplice (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); cyteir (Inst); DaiichI Sankyo (Inst); Daiichi Sankyo/Lilly (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fujifilm (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Iconic Therapeutics (Inst); Iconic Therapeutics (Inst); Iconic Therapeutics (Inst); IgM Biosciences (Inst); Immunitas (Inst); Immunogen (Inst); Immunogen (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Metabomed (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Navire (Inst); NiKang Therapeutics (Inst); Oncorus (Inst); Poseida therapeutics (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Sarah Cannon Research Institute (Inst); Seagan (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Stingthera (Inst); StingThera (Inst); Synthorx (Inst); Synthorx (Inst); Takeda (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tarveda Therapeutics (Inst); Teneothree (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - HCA/Sarah Cannon (Inst)
 
Konstantinos Leventakos
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Inc (Inst); Janssen Biotech (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Mirati Therapeutics (Inst); MJH Life Sciences (Inst); Novartis (Inst); OncLive (Inst); Regeneron (Inst); Takeda (Inst); Targeted Oncology (Inst)
Research Funding - AstraZeneca (Inst); Mirati Therapeutics (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst)
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Kyriakos Papadopoulos
Other Relationship - Abbvie; Amgen; Anheart Therapeutics; Bicycle Therapeutics; BioNTech; Bristol-Myers Squibb; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; F-Star; Fog Pharmaceuticals; Frontier Medicines; Genmab; Incyte; Kezar Life Sciences; Lilly; Merck; Mirati Therapeutics; Monte Rosa Therapeutics; Pfizer; PharmaMar; Revolution Medicines; Sensei Biotherapeutics; Storm Therapeutics; Tempest Therapeutics; Treadwell Therapeutics
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Cesar Augusto Perez
Consulting or Advisory Role - BeiGene; EMD Serono; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Elpiscience (Inst); Genentech (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Merus (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Richard Zuniga
Consulting or Advisory Role - Bristol-Myers Squibb; Flatiron Health; Mirati Therapeutics
Other Relationship - Chemo Mouthpiece
 
Hani Babiker
Consulting or Advisory Role - Celgene; Endocyte; Idera; Myovant Sciences; Novocure
Speakers' Bureau - Guardant Health
 
Candace Haddox
Employment - Dana-Farber Cancer Institute
Honoraria - Horizon CME; i3 Health
Consulting or Advisory Role - AADi; deciphera; SpringWorks Therapeutics
Research Funding - AADi (Inst); ASCO; Cogent Biosciences (Inst); EMD Serono/Merck (Inst); HiFiBiO Therapeutics (Inst); Roche/Genentech (Inst); Tango Therapeutics (Inst); Tubulis GmbH (Inst)
 
Alice Wozniak
Employment - Bristol-Myers Squibb; Mirati Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; Mirati Therapeutics
 
Curtis Chin
Employment - Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
 
Antonella Mazzei
Employment - Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol Myers Squib
 
Zheyi Hu
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Tyler Simpson
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Sanofi
 
Adam Dickinson
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Mirati Therapeutics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Mirati Therapeutics
 
Pasi Jänne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Blueprint Medicines; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Duality Biologics; Eisai; Frontier Medicines; Hongyun Biotech; Ignyta; Lilly; LOXO; Merrimack; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Puma Biotechnology (Inst); Revolution Medicines (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
Expert Testimony - AstraZeneca